Benzonatate

Pronunciation

Dosage Form: capsule

Benzonatate CAPSULES, USP

Rx Only

Benzonatate Description

Benzonatate, a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan- 28-yl p-(butylamino) benzoate. The molecular formula is C30H53NO11 with a molecular weight of 603.7

Slideshow: OTC Medication Use In Pregnancy: Wise or Worrisome?

Each capsule, for oral administration, contains 100 mg or 200 mg of Benzonatate, USP.

Benzonatate Capsules also contain: Alcohol, ammonium hydroxide, D&C Yellow 10, gelatin, glycerin, propylene glycol, purified water, shellac glaze, simethicone and titanium dioxide. In addition, the capsule may contain trace amounts of fractionated coconut oil.

Benzonatate - Clinical Pharmacology

Benzonatate acts peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the cough reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate capsules have no inhibitory effect on the respiratory center in recommended dosage.

Indications and Usage for Benzonatate

Benzonatate capsules are indicated for the symptomatic relief of cough.

Contraindications

Hypersensitivity to Benzonatate or related compounds.

Warnings

Hypersensitivity

Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures.

Psychiatric Effects

Isolated instances of bizarre behavior, including mental confusion and visual hallucinations, have also been reported in patients taking Benzonatate capsules in combination with other prescribed drugs.

Accidental Ingestion and Death in Children

Keep Benzonatate capsules out of reach of children. Accidental ingestion of Benzonatate capsules resulting in death has been reported in children below age 10. Signs and symptoms of overdose have been reported within 15-20 minutes and death has been reported within one hour of ingestion. If accidental ingestion occurs, seek medical attention immediately (see OVERDOSAGE).

Precautions

Benzonatate is chemically related to anesthetic agents of the para-amino-benzoic acid class (e.g. procaine; tetracaine) and has been associated with adverse CNS effects possibly related to a prior sensitivity to related agents or interaction with concomitant medication.

Information for Patients:

Swallow Benzonatate capsules whole. Do not break, chew, dissolve, cut or crush Benzonatate capsules. Release of Benzonatate from the capsule in the mouth can produce a temporary local anesthesia of the oral mucosa and choking could occur. If numbness or tingling of the tongue, mouth, throat, or face occurs, refrain from oral ingestion of food or liquids until the numbness has resolved. If the symptoms worsen or persist, seek medical attention.

Keep Benzonatate capsules out of reach of children. Accidental ingestion resulting in death has been reported in children. Signs and symptoms of overdose have been reported within 15-20 minutes and death has been reported within one hour of ingestion. Signs and symptoms may include restlessness, tremors, convulsions, coma and cardiac arrest. If accidental ingestion occurs, seek medical attention immediately.

Overdosage resulting in death may occur in adults.

Do not exceed a single dose of 200 mg and a total daily dosage of 600 mg. If you miss a dose of Benzonatate capsules, skip that dose and take the next dose at the next scheduled time. Do not take 2 doses of Benzonatate capsules at one time.

Usage in Pregnancy:

Pregnancy Category C. Animal reproduction studies have not been conducted with Benzonatate. It is also not known whether Benzonatate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Benzonatate capsules should be given to a pregnant woman only if clearly needed.

Nursing Mothers:

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk caution should be exercised when Benzonatate capsules are administered to a nursing woman.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

Carcinogenicity, mutagenicity, and reproduction studies have not been conducted with Benzonatate.

Pediatric Use:

Safety and effectiveness in children below the age of 10 have not been established. Accidental ingestion resulting in death has been reported in children below age 10. Keep out of reach of children.

Adverse Reactions

Potential Adverse Reactions to Benzonatate capsules may include:

Hypersensitivity reactions including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule.

CNS: sedation; headache; dizziness; mental confusion; visual hallucinations.

GI: constipation; nausea; GI upset.

Dermatologic: pruritus; skin eruptions.

Other: nasal congestion; sensation of burning in the eyes; vague “chilly” sensation; numbness of the chest; hypersensitivity.

Deliberate or accidental overdose has resulted in death, particularly in children.

Overdosage

Intentional and unintentional overdose may result in death, particularly in children.

The drug is chemically related to tetracaine and other topical anesthetics and shares various aspects of their pharmacology and toxicology. Drugs of this type are generally well absorbed after ingestion.

Signs and Symptoms:

The signs and symptoms of overdose of Benzonatate have been reported within 15-20 minutes. If capsules are chewed or dissolved in the mouth, oropharyngeal anesthesia will develop rapidly, which may cause choking and airway compromise.

CNS stimulation may cause restlessness and tremors which may proceed to clonic convulsions followed by profound CNS depression. Convulsions, coma, cerebral edema and cardiac arrest leading to death have been reported within 1 hour of ingestion.

Treatment:

In case of overdose, seek medical attention immediately. Evacuate gastric contents and administer copious amounts of activated charcoal slurry. Even in the conscious patient, cough and gag reflexes may be so depressed as to necessitate special attention to protection against aspiration of gastric contents and orally administered materials. Convulsions should be treated with a short-acting barbiturate given intravenously and carefully titrated for the smallest effective dosage. Intensive support of respiration and cardiovascular-renal function is an essential feature of the treatment of severe intoxication from overdosage.

Do not use CNS stimulants.

Benzonatate Dosage and Administration

Adults and Children over 10 years of age: Usual dose is one 100 mg or 200 mg capsule three times a day as needed for cough. If necessary to control cough, up to 600 mg daily in three divided doses may be given. Benzonatate Capsules should be swallowed whole. Benzonatate Capsules are not to be broken, chewed, dissolved, cut or crushed.

How is Benzonatate Supplied

Benzonatate capsules, USP 100 mg are clear, yellow liquid filled in oval-shaped softgel capsule, imprinted “133” in white ink. The capsules are available as:

NDC 57664-133-88       Bottles of 100      CRC

NDC 57664-133-13       Bottles of 500

Benzonatate capsules, USP 200 mg are clear, yellow liquid filled in oval-shaped softgel capsule, imprinted “134” in white ink. The capsules are available as:

NDC 57664-134-88       Bottles of 100      CRC

NDC 57664-134-13       Bottles of 500

Store at 20° - 25°C (68° - 77°F). (See USP Controlled Room Temperature).

PROTECT FROM LIGHT.

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). KEEP TIGHTLY CLOSED.

Distributed by:
Caraco Pharmaceutical Laboratories, Ltd.
Detroit, MI 48202

6351T03
Rev. 04/2014

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL- 100 mg 100 count


NDC 57664-133-88

Benzonanate Capsules, USP

100 mg

Rx only

100 Capsules

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL- 200 mg 100 count

NDC 57664-134-88

Benzonanate Capsules, USP

200 mg

Rx only


100 Capsules




Benzonatate 
Benzonatate capsule
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:57664-133
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Benzonatate (Benzonatate) Benzonatate 100 mg
Inactive Ingredients
Ingredient Name Strength
ALCOHOL  
AMMONIA  
D&C YELLOW NO. 10  
GELATIN  
GLYCERIN  
PROPYLENE GLYCOL  
WATER  
SHELLAC  
DIMETHICONE  
TITANIUM DIOXIDE  
MEDIUM-CHAIN TRIGLYCERIDES  
Product Characteristics
Color YELLOW Score no score
Shape OVAL Size 3mm
Flavor Imprint Code 133
Contains         
Packaging
# Item Code Package Description
1 NDC:57664-133-88 100 CAPSULE in 1 BOTTLE
2 NDC:57664-133-13 500 CAPSULE in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA040587 04/07/2008
Benzonatate 
Benzonatate capsule
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:57664-134
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Benzonatate (Benzonatate) Benzonatate 200 mg
Inactive Ingredients
Ingredient Name Strength
ALCOHOL  
AMMONIA  
D&C YELLOW NO. 10  
GELATIN  
GLYCERIN  
PROPYLENE GLYCOL  
WATER  
SHELLAC  
DIMETHICONE  
TITANIUM DIOXIDE  
MEDIUM-CHAIN TRIGLYCERIDES  
Product Characteristics
Color YELLOW Score no score
Shape OVAL Size 5mm
Flavor Imprint Code 134
Contains         
Packaging
# Item Code Package Description
1 NDC:57664-134-88 100 CAPSULE in 1 BOTTLE
2 NDC:57664-134-13 500 CAPSULE in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA040587 04/07/2008
Labeler - Caraco Pharmaceutical Laboratories, Ltd. (146974886)
Establishment
Name Address ID/FEI Operations
Pharmaceutics International Inc. 878265586 MANUFACTURE(57664-133, 57664-134)
Revised: 06/2014
 
Caraco Pharmaceutical Laboratories, Ltd.
Hide
(web5)